Reforming Board-Centered Corporate Governance
Diversifying Capital Exit Strategies
through Innovative and Cross-Industry M&A

Editor's NoteThe global pharmaceutical and biotech industries are experiencing an unprecedented boom in mergers and acquisitions (M&A). By August 2026 alone, over 276 trillion won in investment has poured into the global biotech M&A market, yet there have been no "big deals" involving domestic companies. This is a bitter pill for Korean biotech, whose industrial competitiveness is increasingly recognized on the world stage. In terms of the number of pipelines, Korea ranks third globally, after the United States and China, and there are many new drug companies receiving successive invitations at overseas conferences and exhibitions. The limitations of relying solely on IPOs for capital raising and investment returns are clear. We examine why our biotech technology companies are being overlooked, and seek fundamental solutions both for improving core competitiveness and within capital markets.

['Cold Shoulder for M&A' K-Bio] ① Over 276 Trillion Won in the First Half Only, but Korea—Ranked 3rd Globally—Is Left Out


['Cold Shoulder for M&A' K-Bio] ② Korea Trapped by Data, Clinical Trials, and Governance


['Cold Shoulder for M&A' K-Bio] ③ "Consolidate Pipelines and Focus on Core Competencies and Single Technologies"


In order to revitalize mergers and acquisitions (M&A) within the Korean biotech industry, experts propose solutions such as improving the R&D ecosystem, reforming corporate governance, and introducing unconventional M&A models. The key challenge is whether a bold restructuring to trim sprawling pipelines will be possible.

 

Mansoon Hwang, CEO of Korea Investment Partners, said on August 3, "It is essential to go all-in on a single technology that concentrates the company’s core strengths, and to make courageous decisions to sell off or abandon assets with low chances of success." He added, "From a venture capital perspective, we should also actively utilize private equity funds to acquire promising ventures, maximize pipeline value, and pursue proactive exit strategies by selling to global conglomerates."


Mansoon Hwang, CEO of Korea Investment Partners

Mansoon Hwang, CEO of Korea Investment Partners

View original image

From a governance perspective, many argue for moving away from founder-centric structures to establish properly functioning boards of directors. Korean biotech ventures have often faced criticism for situations where founders serve concurrently as both CEO and board chair, wielding excessive decision-making authority and thus hindering objective company valuation and decisions on timing for mergers or acquisitions.


Hwang emphasized, "From the early stages of a company’s development, it is essential to assemble a transparent board that makes decisions focused solely on the company’s growth rather than the interests of founders or major shareholders. Incentives such as extra points for listing companies operating sound boards, or mandatory recording and storage of board meetings, are also needed." Lee Seung-kyou, Vice Chairman of the Korea Biotechnology Industry Organization (KoreaBIO), likewise stressed, "Controlling unilateral management by CEOs through systems and ensuring transparency in board and audit operations is vital for attracting foreign capital and restoring market trust."


The distorted structure of the domestic capital recovery market, which is highly dependent on IPOs, is also dispersing companies' capabilities. According to statistics from the Korea Venture Capital Association (KVCA), last year M&A accounted for only 4.2% of domestic venture capital investment exits by transaction value, with reliance on IPOs and off-board sales surpassing 90%.


This starkly contrasts with the United States, where figures compiled by the National Venture Capital Association (NVCA) indicate that M&A exits average over 45%. Last year alone, U.S. biotech venture capitalists and other investors recouped 2.3 billion dollars (about 3.312 trillion won) via M&A.


Due to funds being funneled almost exclusively into public markets, Korean companies are often stuck in a vicious cycle, compelled to exhaust resources to meet the listing and accounting standards required to remain listed. An expansion of exit options via the M&A market is expected to boost dynamism throughout the biotech sector.

['M&A Outcasts' K-Bio]③ "Streamline Pipelines and Focus on Core Competencies and Single Technology" View original image

As a concrete alternative to break this bottleneck in capital circulation, the unconventional "reverse M&A" model is also being proposed. Lee argued, "It’s time to consider a model where a biotech with a clear platform technology utilizes funding capital to reverse-acquire a traditional pharmaceutical company, going beyond the conventional pattern of established pharma acquiring ventures. By absorbing the stable cash flows and manufacturing infrastructure of traditional pharmaceutical firms with annual sales in the hundreds of billions of won, biotech ventures can accelerate drug development and secure commercial sustainability."


The inflow of capital from unrelated industries is also cited as a positive alternative. The deal in which confectionery giant Orion invested 548.5 billion won to acquire a 25.7% stake in antibody-drug conjugate (ADC) specialist Legochem Biosciences serves as a model.


Despite racking up cumulative worldwide technology export achievements valued at around 8 trillion won, Legochem Biosciences has struggled to secure the funding required for late-stage clinical development. Hwang assessed, "When large corporations with substantial capital from traditional industries acquire promising ventures, it is an exemplary structure that benefits all parties by alleviating capital market bottlenecks and animating M&A activity."


Institutional support and priming at the government level are also necessary. Lee suggested, "To revitalize the market, it is urgent to create not only early-stage startup acceleration funds but also large-scale funds capable of supporting clinical phase II and above. In addition, regulatory reforms should be implemented to grant real tax benefits, such as corporate tax relief and solutions to inheritance tax issues, upon successful M&A between different industries or when large corporations acquire ventures, thereby reinvigorating the sluggish M&A market."



This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing